Why the study?
Does zileuton or montelukast reduce ischemia/reperfusion-induced arrhythmias in a rat model?
Does zileuton or montelukast reduce ischemia/reperfusion-induced arrhythmias in a rat model?
In a rat model of ischemia/reperfusion, the 5-lipoxygenase inhibitor zileuton, but not the cysteinyl leukotriene receptor antagonist montelukast, effectively reduced reperfusion-induced ventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use of leukotriene modulators for arrhythmias; leaves open translation from rat models to human trials.
Ersöz Gonca (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: